Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Mesoblast Limited    MSB   AU000000MSB8

MESOBLAST LIMITED

(MSB)
  Report  
End-of-day quote. End-of-day quote AUSTRALIAN SECURITIES EXCHANGE LIMITED - 12/13
1.915 AUD   +1.86%
12/04MESOBLAST : Ceasing to be a substantial holder
PU
12/04MESOBLAST : Change of Director's Interest Notice
PU
11/28MESOBLAST : Interview with mesoblast chairman joseph r. swedish 2019 mesoblast annual general meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Mesoblast : and Lonza Enter into Agreement for Commercial Manufacture of Mesoblast's Potential First United States Allogeneic Therapy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/17/2019 | 10:59am EST

Mesoblast (ASX: MSB; Nasdaq:MESO) and Lonza (SWX: LONN) announced today that they have entered into an agreement for commercial manufacture of Mesoblast's lead allogeneic (off-the-shelf) cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease (aGVHD).

This agreement will facilitate inventory build ahead of the planned United States (US) market launch of remestemcel-L and commercial supply to meet Mesoblast's long-term market projections.

Mesoblast expects to complete filing of the rolling Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) by the end of this year. On acceptance of the filing, the product candidate is eligible for FDA priority review under its existing Fast Track designation, providing for an expedited review period. If approved, the US launch of remestemcel-L is expected to occur next year.

The agreement provides for Lonza to expand its Singapore cGMP facilities if required to meet long-term growth and capacity needs for the product. Additionally, it anticipates introduction of new technologies and process improvements which are expected to result in significant increases in yields and efficiencies.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum . Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases. Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.

About Mesoblast

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Two products have been commercialized in Japan and Europe by its licensees, and it has established commercial partnerships in Europe and China for certain Phase 3 assets. In the United States, Mesoblast has initiated submission of a rolling Biologics License Application to the FDA to seek approval of its product candidate for acute graft versus host disease following a successful Phase 3 trial, and is completing Phase 3 trials for its advanced heart failure and chronic low back pain product candidates. Mesoblast's proprietary manufacturing process yields industrial-scale, frozen, off-the-shelf, cellular medicines based on its mesenchymal lineage cell platform technology. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Melbourne, New York, Singapore and Texas and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).

Mesoblast's Forward-Looking Statements

This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forwardlooking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the timing, progress and results of Mesoblast's preclinical and clinical studies; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forwardlooking statements. We do not undertake any obligations to publicly update or revise any forwardlooking statements, whether as a result of new information, future developments or otherwise.

Contact:

Tel: +41 61 316 8782

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
LONZA GROUP -0.24% 335.6 Delayed Quote.32.08%
MESOBLAST LIMITED 1.86% 1.915 End-of-day quote.62.07%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MESOBLAST LIMITED
12/04MESOBLAST : Ceasing to be a substantial holder
PU
12/04MESOBLAST : Change of Director's Interest Notice
PU
11/28MESOBLAST : Interview with mesoblast chairman joseph r. swedish 2019 mesoblast a..
AQ
11/27MESOBLAST : Finanical Results for the Quarter Ended September 30, 2019
AQ
11/25Mesoblast Finanical Results for the Quarter Ended September 30, 2019
GL
11/21Mesoblast to Host Analyst Call on Financial Results for First Quarter Ended S..
GL
10/31MESOBLAST : Quarterly cash flow report
AQ
10/30MESOBLAST LIMITED : - Appointment of Joint Company Secretary
AQ
10/28MESOBLAST : Annual Report to shareholders
PU
10/28MESOBLAST : Notice of General Meeting/Proxy Form
PU
More news
Financials (AUD)
Sales 2020 72,1 M
EBIT 2020 -77,6 M
Net income 2020 -91,4 M
Debt 2020 68,6 M
Yield 2020 -
P/E ratio 2020 -5,33x
P/E ratio 2021 -6,76x
EV / Sales2020 15,1x
EV / Sales2021 8,86x
Capitalization 1 021 M
Chart MESOBLAST LIMITED
Duration : Period :
Mesoblast Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MESOBLAST LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,73  AUD
Last Close Price 1,92  AUD
Spread / Highest target 448%
Spread / Average Target 199%
Spread / Lowest Target -16,4%
EPS Revisions
Managers
NameTitle
Silviu Itescu Chief Executive Officer, MD & Executive Director
Joseph R. Swedish Non-Executive Chairman
Joshua Muntner Chief Financial Officer
Fred Grossman Chief Medical Officer
Karen Segal Head-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
MESOBLAST LIMITED62.07%701
IQVIA HOLDINGS INC.24.69%28 106
LONZA GROUP32.08%25 344
INCYTE CORPORATION43.91%19 711
SEATTLE GENETICS, INC.100.97%19 516
CELLTRION, INC.--.--%18 622